Biomarker ID | 1629 |
PMID | 31031850 |
Year | 2019 |
Biomarker | CCNB2 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.697 |
Effect on Pathways | Pathways include: Cyclin B2-mediated events, Control of cell cycle and breast tumor growth by estrogen-responsive protein Efp, Cyclin A/B1-associated events during G2/M transition, Delta Np63 pathway, G2/M checkpoints |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis |
Senstivity | NA |
Specificity | NA |
AUC | 0.6299 |
Accuracy | NA |
Level Of Significance | p < 0.001469 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |